XML 39 R26.htm IDEA: XBRL DOCUMENT v3.23.1
Stock Option Plan (Tables)
12 Months Ended
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock Option Activity
Stock option activity under the Company's 2019 Plan is set forth below:
Number of
Options
Weighted-
Average
Exercise Price
Weighted-
Average
Remaining
Contractual
Term (Years)
Aggregate
Intrinsic
Value
Outstanding, December 31, 2021
2,014,330 $12.10 7.87$5,428 
Granted63,000 $5.25 
Exercised(245,186)$0.26 
Forfeited(257,982)$16.09 
Expired(152,927)$13.73 
Outstanding, December 31, 2022
1,421,235 $12.94 7.09$483 
Vested and expected to vest, December 31, 2022
1,421,235 $12.94 7.09$483 
Options exercisable, December 31, 2022
1,129,333 $12.94 6.89$483 
Schedule of Share-based Payment Arrangement, Restricted Stock Unit, Activity
Restricted stock unit activity under the Company's 2019 Plan is set forth below:
Number of
Shares
Weighted-
Average
Grant Date Fair Value
Aggregate
Intrinsic
Value
Outstanding, December 31, 2021
415,325 $16.54 $4,830 
Awards granted1,076,725 $5.89 
Awards released(100,586)$16.55 
Awards canceled(355,256)$11.29 
Outstanding, December 31, 2022
1,036,208 $7.28 $2,487 
Schedule of Fair Value Assumptions, Stock Options
The fair value of employee stock options was estimated using the following assumptions in the Black-Scholes options pricing model to determine the fair value of stock options granted:
 Year Ended December 31,
 20222021
Expected volatility
54%
56%-60%
Risk-free interest rate
3.4%
0.8%-1.1%
Dividend yield
Expected term (in years)
5.5
5.5-6.1
The following assumptions were used to calculate the stock-based compensation for each stock purchase right granted under the ESPP:
 Year Ended December 31,
 20222021
Expected volatility
45%-57%
45%-60%
Risk-free interest rate
0.6%-3.3%
0.1%
Dividend yield
Expected term (in years)0.50.5
Schedule of Non-cash Stock-based Compensation Expense
Total non-cash stock-based compensation expense recorded related to options granted, restricted stock units granted and stock purchase rights granted under the ESPP in the statement of operations is as follows (in thousands):
 
 Year Ended December 31,
 20222021
Cost of revenue$213 $164 
Selling, general and administrative3,860 3,943 
Research and development631 621 
Total$4,704 $4,728 
Schedule of Common Stock Reserved For Future Issuance
Common stock reserved for future issuance consists of the following at December 31, 2022:
Warrants to purchase common stock1,214,059 
Common stock option grants issued and outstanding1,421,235 
Common stock reserved for issuance upon vesting of outstanding restricted stock units1,036,370 
Common shares available for grant under the 2019 Plan1,452,435 
Common shares available for future issuance under ESPP413,425 
Total5,537,524